HTB

Conference reports

Interruption of treatment is safe for those who started too early

T20 is cost effective for UK purchasers

Intrauterine exposure to efavirenz

African patients and adherence in the UK

Five-year results of Kaletra-based therapy in treatment-naïve HIV patients

IL-2 effectively increases CD4 count in people with low CD4 nadir

Hepatitis coinfection: incidence in Europe and response to transplant

Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)

13th International Conference on AIDS and STIs in Africa (ICASA), 21-26 September 2003, Nairobi

STIs in resource limited settings

43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago

ddI may retain activity in nucleoside experienced patients

Studies and strategies with existing drugs

Incremental progress with new antiviral drugs

Newer nucleoside analogues show fewer adverse effects

43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago

South African AIDS Conference, 3-6 August 2003, Durban

Township project is a model for care in resource poor settings

Projects band together to buy lowest-cost generic drugs

MTCT-Plus operates in Cote D’Ivoire, Kenya, Mozambique, Rwanda, South Africa, Thailand, Uganda and Zambia

Further reports from 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, 13-16 July 2003

New atazanavir information

Boosted PI therapy antiretrovirals in treatment-experienced patients: SQV/r, ATV, ATV/r

HIV viral dynamics: viral fitness, genetic diversity, progression, co-receptor use

Pulmonary hypertension: finally a treatment trial!

XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003

Transmission of drug resistance – at 11% in Europe and 17% in the UK

HIV coinfection, reinfection and superinfection

Single-dose nevirapine resistance in over 75% of mothers

Transmission of drug resistant virus does not revert to wild-type and does not appear ‘less fit’

Standard genotype assays may miss 75% of mutations when present in less than 35% of plasma sample

Low-level resistance and minority populations: cross resistance between nevirapine and efavirenz occurs even in the absence of genotypic mutations found using population sequencing

Persistent effect of d4T and 3TC, but not NNRTIs in the presence of associated genotypic mutations

Replicative capacity results complicated by minority wild-type virus

Tenofovir, resistance and K65R and concomitant nucleosides

Response to STI is determined by virus rather than immunological response

Why resistance rarely develops with viral suppression <50 copies/mL

Long-term persistence of distinct mutations in genital tract

5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris

Underlying mechanisms: adipocytes and cytokines

More mitochondrial DNA depletion

IMT and cardiovascular risk

Reduced bone mineral density in HIV-positive women

Rosiglitazone with insulin resistance

Additional benefits of exercise with metformin

Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir

Facial fat loss – measuring and treatment

Uridine treatment for mitochondrial toxicity

Breast enlargement in men and testosterone treatment

Severe efavirenz psychotic events

Treatment interruption: a real choice

2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris

Nevirapine and MTCT: the single-dose backlash

Triple nucleoside combinations fail patients again

Nucleoside-sparing regimens

Dual boosted PIs in salvage therapy

BMS reports on atazanavir efficacy and safety in treatment experienced patients

Unsupervised treatment interruptions are associated with increased risk of AIDS or death

Uridine as a potential treatment for NRTI related mitochondrial toxicity

Long term exposure to nucleoside analogues and peripheral nerve function

Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy

First results from ESPRIT study: CD4 response to IL-2 is associated with higher nadir and baseline CD4 and younger age

Lessons learned from early HAART in acute HIV infection

CD4 cell reconstitution is significantly slower in older patients

Pharmacology studies at the 2nd IAS conference

Post navigation